Detecting early lung changes using CO2 analysis
Recognition of Early Pulmonary Structural Changes by Using Real-time High Fidelity Expiratory CO2 Analysis
This study is testing a new way to spot early lung changes in people with COPD or interstitial lung diseases by analyzing their breath to help catch problems sooner.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Graz Academic / other |
| Locations | 1 site (Graz, Styria) |
| Trial ID | NCT05092035 on ClinicalTrials.gov |
What this trial studies
This study aims to identify and characterize structural changes in the airways and lung vessels caused by chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD) through real-time high fidelity expiratory CO2 analysis. The goal is to detect these changes at an early stage, before standard methods like pulmonary function tests show alterations. By focusing on patients with COPD, ILD, or those at risk, the study seeks to improve early recognition and treatment of these conditions, potentially preventing further disease progression and complications.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with COPD, ILD, or smokers and non-smokers without pulmonary diseases who are undergoing right heart catheterization for suspected pulmonary hypertension.
Not a fit: Patients with contraindications for lung function testing or those with acute life-threatening diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier diagnosis and intervention for patients with COPD and ILD, improving their long-term outcomes.
How similar studies have performed: While the approach of using high fidelity expiratory CO2 analysis is innovative, similar studies have shown promise in early detection of pulmonary changes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * all male and female patients older than 18 years who have COPD, ILD or are smokers and non smokers without pulmonary diseases. * right heart catheterization performed due to to suspected pulmonary hypertension and further clinical investigation like echocardiography, lung function testing, 6-minute walk test, laboratory testing and blood gas analysis. * written informed consent Exclusion Criteria: * contraindication for lung function testing * acute life-threatening disease (including acute myocardiac infarction, pulmonary embolism, large aortic aneurysma, pneumothorax, opthalmic, brain, abdominal or thoracic surgery within the last 4 weeks, hemoptysis).
Where this trial is running
Graz, Styria
- Department of Internal Medicine, Pulmonology — Graz, Styria, Austria (Recruiting)
Study contacts
- Principal investigator: Horst Olschewski, Prof. — Devision of Pulmonology, Medical University Hospital of Graz, Austria
- Study coordinator: Horst Olschewski, Prof.
- Email: Horst.Olschweski@medunigraz.at
- Phone: +43 316 385-12183
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.